Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.

Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, Escara-Wilke J, Leander KR, Defeo-Jones D, Hwang C, Sanda MG.

Prostate. 2010 Jun 15;70(9):1002-11. doi: 10.1002/pros.21134.

2.

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.

Cherrin C, Haskell K, Howell B, Jones R, Leander K, Robinson R, Watkins A, Bilodeau M, Hoffman J, Sanderson P, Hartman G, Mahan E, Prueksaritanont T, Jiang G, She QB, Rosen N, Sepp-Lorenzino L, Defeo-Jones D, Huber HE.

Cancer Biol Ther. 2010 Apr 1;9(7):493-503. Epub 2010 Apr 1.

3.

Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.

Li Y, Liang J, Siu T, Hu E, Rossi MA, Barnett SF, Defeo-Jones D, Jones RE, Robinson RG, Leander K, Huber HE, Mittal S, Cosford N, Prasit P.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):834-6. doi: 10.1016/j.bmcl.2008.12.017. Epub 2008 Dec 7.

PMID:
19097777
4.

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N.

PLoS One. 2008 Aug 26;3(8):e3065. doi: 10.1371/journal.pone.0003065.

5.

The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.

Siu T, Li Y, Nagasawa J, Liang J, Tehrani L, Chua P, Jones RE, Defeo-Jones D, Barnett SF, Robinson RG.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4191-4. doi: 10.1016/j.bmcl.2008.05.084. Epub 2008 May 24.

PMID:
18550373
6.

Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors.

Siu T, Liang J, Arruda J, Li Y, Jones RE, Defeo-Jones D, Barnett SF, Robinson RG.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4186-90. doi: 10.1016/j.bmcl.2008.05.085. Epub 2008 May 24.

PMID:
18539456
7.

Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.

Bilodeau MT, Balitza AE, Hoffman JM, Manley PJ, Barnett SF, Defeo-Jones D, Haskell K, Jones RE, Leander K, Robinson RG, Smith AM, Huber HE, Hartman GD.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3178-82. doi: 10.1016/j.bmcl.2008.04.074. Epub 2008 May 1.

PMID:
18479914
8.

Rapid assembly of diverse and potent allosteric Akt inhibitors.

Wu Z, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Kohl NE, Hartman GD, Bilodeau MT.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2211-4. doi: 10.1016/j.bmcl.2007.10.023. Epub 2007 Oct 17.

PMID:
18296048
9.

Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.

Hartnett JC, Barnett SF, Bilodeau MT, Defeo-Jones D, Hartman GD, Huber HE, Jones RE, Kral AM, Robinson RG, Wu Z.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2194-7. doi: 10.1016/j.bmcl.2007.12.040. Epub 2007 Dec 23.

PMID:
18294842
10.

Development of pyridopyrimidines as potent Akt1/2 inhibitors.

Wu Z, Hartnett JC, Neilson LA, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Hartman GD, Bilodeau MT.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1274-9. doi: 10.1016/j.bmcl.2008.01.054. Epub 2008 Jan 19.

PMID:
18249537
11.

Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.

Zhao Z, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huber HE, Duggan ME, Lindsley CW.

Bioorg Med Chem Lett. 2008 Jan 1;18(1):49-53. Epub 2007 Nov 13.

PMID:
18054229
12.

Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.

DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR, McAvoy E, Robinson RG, Duggan ME, Lindsley CW, Zhao Z, Huber HE, Jones RE.

Mol Cancer Ther. 2005 Feb;4(2):271-9.

13.

Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors.

Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME, Lindsley CW.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):905-9.

PMID:
15686884
14.

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.

Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4.

PMID:
15664853
15.

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.

Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, Kahana JA, Kral AM, Leander K, Lee LL, Malinowski J, McAvoy EM, Nahas DD, Robinson RG, Huber HE.

Biochem J. 2005 Jan 15;385(Pt 2):399-408.

16.

A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.

DeFeo-Jones D, Brady SF, Feng DM, Wong BK, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Pawluczyk JM, Wai J, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Garsky VM, Freidinger R, Oliff A, Jones RE.

Mol Cancer Ther. 2002 May;1(7):451-9.

17.

Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.

Brady SF, Pawluczyk JM, Lumma PK, Feng DM, Wai JM, Jones R, DeFeo-Jones D, Wong BK, Miller-Stein C, Lin JH, Oliff A, Freidinger RM, Garsky VM.

J Med Chem. 2002 Oct 10;45(21):4706-15.

PMID:
12361397
18.

The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.

Garsky VM, Lumma PK, Feng DM, Wai J, Ramjit HG, Sardana MK, Oliff A, Jones RE, DeFeo-Jones D, Freidinger RM.

J Med Chem. 2001 Nov 22;44(24):4216-24.

PMID:
11708923
19.

PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.

Wong BK, DeFeo-Jones D, Jones RE, Garsky VM, Feng DM, Oliff A, Chiba M, Ellis JD, Lin JH.

Drug Metab Dispos. 2001 Mar;29(3):313-8.

PMID:
11181501
20.

A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo.

DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Wai J, Senderak ET, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Freidinger R, Huff J, Oliff A, Jones RE.

Nat Med. 2000 Nov;6(11):1248-52.

PMID:
11062536
21.

Characterization of the retinoblastoma binding proteins RBP1 and RBP2.

Fattaey AR, Helin K, Dembski MS, Dyson N, Harlow E, Vuocolo GA, Hanobik MG, Haskell KM, Oliff A, Defeo-Jones D, et al.

Oncogene. 1993 Nov;8(11):3149-56.

PMID:
8414517
22.

Papillomavirus E7 protein binding to the retinoblastoma protein is not required for viral induction of warts.

Defeo-Jones D, Vuocolo GA, Haskell KM, Hanobik MG, Kiefer DM, McAvoy EM, Ivey-Hoyle M, Brandsma JL, Oliff A, Jones RE.

J Virol. 1993 Feb;67(2):716-25.

23.

Comparison of the binding of the human papillomavirus type 16 and cottontail rabbit papillomavirus E7 proteins to the retinoblastoma gene product.

Haskell KM, Vuocolo GA, Defeo-Jones D, Jones RE, Ivey-Hoyle M.

J Gen Virol. 1993 Jan;74 ( Pt 1):115-9.

PMID:
8380832
24.

Human papillomavirus type 16 E7 protein inhibits DNA binding by the retinoblastoma gene product.

Stirdivant SM, Huber HE, Patrick DR, Defeo-Jones D, McAvoy EM, Garsky VM, Oliff A, Heimbrook DC.

Mol Cell Biol. 1992 May;12(5):1905-14.

25.

Purification and characterization of a functionally homogeneous 60-kDa species of the retinoblastoma gene product.

Edwards GM, Huber HE, DeFeo-Jones D, Vuocolo G, Goodhart PJ, Maigetter RZ, Sanyal G, Oliff A, Heimbrook DC.

J Biol Chem. 1992 Apr 25;267(12):7971-4. Erratum in: J Biol Chem 1992 Jul 5;267(19):13780.

26.

Characterization of functional HPV-16 E7 protein produced in Escherichia coli.

Patrick DR, Zhang K, Defeo-Jones D, Vuocolo GR, Maigetter RZ, Sardana MK, Oliff A, Heimbrook DC.

J Biol Chem. 1992 Apr 5;267(10):6910-5.

27.

Expression of growth factor-toxin fusion proteins.

Edwards GM, Defeo-Jones D, Stirdivant SM, Heimbrook DC, Oliff A.

Targeted Diagn Ther. 1992;7:425-37. Review. No abstract available.

PMID:
1633303
28.

Antibodies specific for the human retinoblastoma protein identify a family of related polypeptides.

Hu QJ, Bautista C, Edwards GM, Defeo-Jones D, Jones RE, Harlow E.

Mol Cell Biol. 1991 Nov;11(11):5792-9.

29.

Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product.

Defeo-Jones D, Huang PS, Jones RE, Haskell KM, Vuocolo GA, Hanobik MG, Huber HE, Oliff A.

Nature. 1991 Jul 18;352(6332):251-4.

PMID:
1857421
30.

Mammalian cell lines engineered to identify inhibitors of specific signal transduction pathways.

Jones RE, Defeo-Jones D, McAvoy EM, Vuocolo GA, Wegrzyn RJ, Haskell KM, Oliff A.

Oncogene. 1991 May;6(5):745-51.

PMID:
1711189
31.

Lovastatin selectively inhibits ras activation of the 12-O-tetradecanoylphorbol-13-acetate response element in mammalian cells.

Defeo-Jones D, McAvoy EM, Jones RE, Vuocolo GA, Haskell KM, Wegrzyn RJ, Oliff A.

Mol Cell Biol. 1991 Apr;11(4):2307-10.

32.

Biological activity of a transforming growth factor-alpha--Pseudomonas exotoxin fusion protein in vitro and in vivo.

Heimbrook DC, Stirdivant SM, Ahern JD, Balishin NL, Patrick DR, Edwards GM, Defeo-Jones D, FitzGerald DJ, Pastan I, Oliff A.

J Ind Microbiol. 1991 Apr;7(3):203-7.

PMID:
1367127
33.

Molecular and biochemical approaches to structure--function analysis of transforming growth factor alpha.

Defeo-Jones D, Tai JY, Oliff A.

Methods Enzymol. 1991;198:191-200. No abstract available.

PMID:
1857218
34.

Identification of HPV-16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein.

Jones RE, Wegrzyn RJ, Patrick DR, Balishin NL, Vuocolo GA, Riemen MW, Defeo-Jones D, Garsky VM, Heimbrook DC, Oliff A.

J Biol Chem. 1990 Aug 5;265(22):12782-5.

35.

Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts.

Heimbrook DC, Stirdivant SM, Ahern JD, Balishin NL, Patrick DR, Edwards GM, Defeo-Jones D, FitzGerald DJ, Pastan I, Oliff A.

Proc Natl Acad Sci U S A. 1990 Jun;87(12):4697-701.

36.
37.
38.

Spontaneously transformed NRK cells lose their mitogenic response to epidermal growth factor.

Wegrzyn RJ, Defeo-Jones D, Heimbrook DC, Wallen J, Kiefer DM, Riemen MW, Oliff A.

Growth Factors. 1989;1(3):227-36.

PMID:
2483520
39.

Structure-function analysis of synthetic and recombinant derivatives of transforming growth factor alpha.

Defeo-Jones D, Tai JY, Wegrzyn RJ, Vuocolo GA, Baker AE, Payne LS, Garsky VM, Oliff A, Riemen MW.

Mol Cell Biol. 1988 Aug;8(8):2999-3007.

40.

Tumors secreting human TNF/cachectin induce cachexia in mice.

Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH.

Cell. 1987 Aug 14;50(4):555-63.

PMID:
3607879
41.

Nucleotide sequence of the two rat cellular rasH genes.

Ruta M, Wolford R, Dhar R, Defeo-Jones D, Ellis RW, Scolnick EM.

Mol Cell Biol. 1986 May;6(5):1706-10.

42.

Mammalian and yeast ras gene products: biological function in their heterologous systems.

DeFeo-Jones D, Tatchell K, Robinson LC, Sigal IS, Vass WC, Lowy DR, Scolnick EM.

Science. 1985 Apr 12;228(4696):179-84.

PMID:
3883495
43.

Assignment of three rat cellular RAS oncogenes to chromosomes 1, 4, and X.

Szpirer J, Defeo-Jones D, Ellis RW, Levan G, Szpirer C.

Somat Cell Mol Genet. 1985 Jan;11(1):93-7.

PMID:
3856333
44.

Expression and characterization of ras mRNAs from Saccharomyces cerevisiae.

Temeles GL, DeFeo-Jones D, Tatchell K, Ellinger MS, Scolnick EM.

Mol Cell Biol. 1984 Nov;4(11):2298-305.

45.

Requirement of either of a pair of ras-related genes of Saccharomyces cerevisiae for spore viability.

Tatchell K, Chaleff DT, DeFeo-Jones D, Scolnick EM.

Nature. 1984 Jun 7-13;309(5968):523-7.

PMID:
6328319
46.

Nucleotide sequence of two rasH related-genes isolated from the yeast Saccharomyces cerevisiae.

Dhar R, Nieto A, Koller R, DeFeo-Jones D, Scolnick EM.

Nucleic Acids Res. 1984 Apr 25;12(8):3611-8.

47.

Saccharomyces cerevisiae synthesizes proteins related to the p21 gene product of ras genes found in mammals.

Papageorge AG, Defeo-Jones D, Robinson P, Temeles G, Scolnick EM.

Mol Cell Biol. 1984 Jan;4(1):23-9.

48.

ras-Related gene sequences identified and isolated from Saccharomyces cerevisiae.

DeFeo-Jones D, Scolnick EM, Koller R, Dhar R.

Nature. 1983 Dec 15-21;306(5944):707-9.

PMID:
6318116

Supplemental Content

Loading ...
Support Center